SCHEMBL3511754

SCHEMBL3511754

CC(C)c1ccc(OS(C)(=O)=O)cc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA2 P00918 4/20 0.50
CA12 O43570 3/20 0.50
CA9 Q16790 2/20 0.50
CA1 P00915 1/20 0.50
MMP2 P08253 2/20 0.41
MMP7 P09237 2/20 0.41
MMP9 P14780 2/20 0.41
MMP14 P50281 2/20 0.41
MMP1 P03956 1/20 0.41
IDO1 P14902 2/20 0.41
ALDH1A1 P00352 3/20 0.41
CXCR2 P25025 2/20 0.41
MEN1 O00255 1/20 0.41
RAB9A P51151 1/20 0.41
KMT2A Q03164 1/20 0.41
KDM4E B2RXH2 2/20 0.40
GAA P10253 2/20 0.40
TYR P14679 1/20 0.40
CXCR1 P25024 1/20 0.40
LMNA P02545 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1820936 0.85 ALDH1A1 (0.43) CA2CA12CA9CA1MMP2
SCHEMBL1826082 0.83 MMP2 (0.39) CA2CA12CA9CA1MMP2
SCHEMBL575589 0.83 CA2 (0.52) CA2CA12CA9CA1MMP2
SCHEMBL1826341 0.82 CA2 (0.39) CA2CA12CA9CA1MMP2
SCHEMBL7625242 0.82 MMP2 (0.38) CA2CA12CA9CA1MMP2
SCHEMBL24279530 0.82 CA2 (0.50) CA2CA12CA9CA1IDO1
SCHEMBL24604531 0.81 CA2 (0.53) CA2CA12CA9CA1ALDH1A1
SCHEMBL10172545 0.81 CA2 (0.71) CA2CA12CA9CA1
SCHEMBL1827699 0.80 ALDH1A1 (0.40) CA2CA12CA9CA1MMP2
SCHEMBL1823366 0.80 ALDH1A1 (0.51) MMP2MMP7MMP9MMP14MMP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11701354-B2 Pyrazolo[3,4-b]pyrazine derivatives as SHP2 phosphatase inhibitors D. E. SHAW RESEARCH, LLC (US) 2023-07-18 US disclosed
US-11701354-B2 Pyrazolo[3,4-b]pyrazine derivatives as SHP2 phosphatase inhibitors D. E. SHAW RESEARCH, LLC (US) 2023-07-18 US disclosed
EP-3515916-B1 SHP2 PHOSPHATASE INHIBITORS AND METHODS OF USE THEREOF RELAY THERAPEUTICS INC (US) 2023-06-07 EP disclosed
US-20230017045-A1 PYRIDINE AND PYRIMIDINE CARBOXYLATE HERBICIDES AND METHODS OF USE THEREOF DOW AGROSCIENCES LLC (US) 2023-01-19 US disclosed
US-11529348-B2 2022-12-20 US disclosed
US-11529347-B2 SHP2 phosphatase inhibitors and methods of use thereof RELAY THERAPEUTICS, INC. (US) 2022-12-20 US disclosed
EP-3257510-B1 LACTATE DEHYDROGENASE INHIBITOR AND ANTIEPILEPTIC DRUG CONTAINING SAME NAT UNIV CORPORATION OKAYAMA UNIV (JP) 2021-10-20 EP disclosed
US-20200392161-A1 SHP2 PHOSPHATASE INHIBITORS AND METHODS OF USE THEREOF SCHRÖDINGER, INC. 2020-12-17 US disclosed
US-20200253969-A1 PYRAZOLO[3,4-B]PYRAZINE DERIVATIVES AS SHP2 PHOSPHATASE INHIBITORS SCHRODINGER, LLC 2020-08-13 US disclosed
US-20200062760-A1 SHP2 PHOSPHATASE INHIBITORS AND METHODS OF USE THEREOF RELAY THERAPEUTICS, INC. 2020-02-27 US disclosed
US-20190307745-A1 SHP2 PHOSPHATASE INHIBITORS AND METHODS OF USE THEREOF RELAY THERAPEUTICS, INC. 2019-10-10 US disclosed
WO-2019165073-A1 SHP2 PHOSPHATASE INHIBITORS AND METHODS OF USE THEREOF RELAY THERAPEUTICS, INC. (US) 2019-08-29 WO disclosed
US-20180015068-A1 LACTATE DEHYDROGENASE INHIBITOR AND ANTIEPILEPTIC DRUG CONTAINING THE SAME NATIONAL UNIVERSITY CORPORATION OKAYAMA UNIVERSITY (JP) 2018-01-18 US disclosed
US-20100286145-A1 ISOPHTHALAMIDE DERIVATIVES INHIBITING BETA-SECRETASE ACTIVITY COMENTIS, INC. (US) 2010-11-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200062760-A1 SHP2 PHOSPHATASE INHIBITORS AND METHODS OF USE THEREOF PTPRCAP, PTPRJ, PTPRC CA2 638/4885CA12 2026/4885CA9 1673/4885
US-20190307745-A1 SHP2 PHOSPHATASE INHIBITORS AND METHODS OF USE THEREOF PTPN21, PTPN5, PTPN1 CA2 517/4885CA12 490/4885CA9 485/4885
US-20230017045-A1 PYRIDINE AND PYRIMIDINE CARBOXYLATE HERBICIDES AND METHODS OF USE THEREOF PDXK, DPYD, DDT CA2 1070/4885CA12 1796/4885CA9 1525/4885
US-11529348-B2 PTPRCAP, PTPN2, PTPN6 CA2 2654/4885CA12 4353/4885CA9 4620/4885
US-20180015068-A1 LACTATE DEHYDROGENASE INHIBITOR AND ANTIEPILEPTIC DRUG CONTAINING THE SAME LDHA, LDHB, ALDH5A1 CA2 229/4885CA12 846/4885CA9 338/4885
US-11529347-B2 SHP2 phosphatase inhibitors and methods of use thereof PTPN21, PTPN22, PTPN5 CA2 535/4885CA12 585/4885CA9 444/4885
US-20100286145-A1 ISOPHTHALAMIDE DERIVATIVES INHIBITING BETA-SECRETASE ACTIVITY BACE1, BACE2, APP CA2 3501/4885CA12 4172/4885CA9 4272/4885
US-11701354-B2 Pyrazolo[3,4-b]pyrazine derivatives as SHP2 phosphatase inhibitors PTPN5, PTPN2, PTPN7 CA2 2216/4885CA12 4504/4885CA9 4717/4885
US-20200253969-A1 PYRAZOLO[3,4-B]PYRAZINE DERIVATIVES AS SHP2 PHOSPHATASE INHIBITORS PTPN5, PTPN2, PPM1A CA2 1740/4885CA12 3626/4885CA9 3693/4885
US-20200392161-A1 SHP2 PHOSPHATASE INHIBITORS AND METHODS OF USE THEREOF PTPRCAP, PTPRJ, PTPRC CA2 1807/4885CA12 3582/4885CA9 3054/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.